Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high‐risk proliferative diabetic retinopathy (IBeHi study)

. Purpose: To evaluate the effects of panretinal photocoagulation (PRP) compared with PRP plus intravitreal bevacizumab on best corrected visual acuity (BCVA) and total area of fluorescein leakage from active new vessels (NVs) in patients with high‐risk proliferative diabetic retinopathy (PDR). Met...

Full description

Saved in:

Bibliographic Details
Published in:	Acta ophthalmologica (Oxford, England) Vol. 86; no. 4; pp. 385 - 389
Main Authors:	Tonello, Matheus, Costa, Rogério A., Almeida, Felipe P. P., Barbosa, José C., Scott, Ingrid U., Jorge, Rodrigo
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Publishing Ltd 01-06-2008
Subjects:	Adult Aged angiogenesis Angiogenesis Inhibitors - administration & dosage Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Bevacizumab Cell Division - drug effects Combined Modality Therapy diabetes Diabetic Retinopathy - drug therapy Diabetic Retinopathy - surgery Female Follow-Up Studies Humans Injections laser Laser Coagulation - methods Male Middle Aged Prospective Studies Risk Factors treatment Treatment Outcome vascular endothelial growth factor Visual Acuity Vitreous Body
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	. Purpose: To evaluate the effects of panretinal photocoagulation (PRP) compared with PRP plus intravitreal bevacizumab on best corrected visual acuity (BCVA) and total area of fluorescein leakage from active new vessels (NVs) in patients with high‐risk proliferative diabetic retinopathy (PDR). Methods: We carried out a prospective study of patients with high‐risk PDR and no prior laser treatment who were randomly assigned to receive PRP (PRP group) or PRP plus intravitreal injection of 1.5 mg of bevacizumab (PRP‐plus group). In all patients, the PRP was administered at two time‐points (weeks 1 and 3), with the intravitreal bevacizumab delivered at the end of the second laser episode in the PRP‐plus group. Standardized ophthalmic evaluation including Early Treatment Diabetic Retinopathy Study BCVA as well as stereoscopic fundus photography and fluorescein angiography were performed at baseline and at weeks 4, 9 (± 1) and 16 (± 2). Main outcome measures included changes in BCVA and in total area of fluorescein leakage from active NVs. Results: Twenty‐two (n = 30 eyes) consecutive patients completed the 16‐week follow‐up. There was no significant difference between the PRP and PRP‐plus groups with respect to age, gender, type or duration of diabetes, area of fluorescein leakage from active NVs or BCVA. No significant difference in BCVA was observed between the groups throughout the study period. However, the total area of actively leaking NVs was significantly reduced in the PRP‐plus group compared with the PRP group at weeks 4, 9 and 16 (p < 0.001). No major adverse events were identified. Conclusions: In the short‐term, the adjunctive use of intravitreal bevacizumab with PRP was associated with a greater reduction in the area of active leaking NVs than PRP alone in patients with high‐risk PDR.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-News-1 ObjectType-Feature-3
ISSN:	1755-375X 1755-3768
DOI:	10.1111/j.1600-0420.2007.01056.x